Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose- (Q38804812)
Jump to navigation
Jump to search
scientific article published on 4 May 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose- |
scientific article published on 4 May 2017 |
Statements
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study (English)
Jung-Min Lee
Ashley Cimino-Mathews
Cody J Peer
Alexandra Zimmer
Stanley Lipkowitz
Christina M Annunziata
Liang Cao
Maria I Harrell
Elizabeth M Swisher
Nicole Houston
Janis M Taube
Elizabeth Thompson
Aleksandra Ogurtsova
Haiying Xu
Jeffers Nguyen
Tony W Ho
William D Figg